Evopoint Biosciences (SHA:688837) priced its initial public offering in Shanghai's STAR Market board of 65.3 million shares, or 15% of its post-IPO share capital, at 27.60 yuan each to raise 1.80 billion yuan, according to a filing with the Shanghai bourse.
The biopharmaceutical company will use the proceeds to fund research and development and working capital.
Online and offline subscriptions will be on Sept. 3.
Guotai Haitong Securities serves as lead underwriter, with China Galaxy Securities as joint lead underwriter.